All clinical laboratory tests will be performed in a CLIA and/or ISO -certified facility. Non -clinical tests (i.e., IHC/PCR/ELISA tests for evaluation of TAPA expression, ELISPOT for evaluation of immune response, etc.) will be performed in CLIA and/or ISO -certified facilities whenever possible. 4.2.3 Final Study Visit 1. The final study visit will take plac e 30 days (Day 45) +/ - 3 days after the last DC vaccination. Procedures will include a blood draw and DTH skin tests for responsiveness to TAPAs. 2. Laboratory tests at the final study visit will include serum tumor markers (if indicated), hepatic and renal profile, CBC, and differential leukocyte counts. 3. Appropriate imaging studies and other relevant tests for determining disease status (i.e., cytogenetics, etc.) will be also obtained as clinically indicated . 4.2.4 Post-Study Follow-up 1. Blood for immune assays (up to 100 ml) will be drawn 7 days prior to t he first vaccination and again at day 22 and day 45. KIROVAX 003 Date: August 22, 2018- Version 00 7 CONFIDENTIAL Page 30 of 47 4.2.5 Discontinuation Visit 1. Will be identical to final study laboratories/procedures. Procedures will include a blood draw and skin tests for responsiveness to TAPAs. 2. Laboratory tests at the final study visit will include hepatic and renal profile, CBC and differential leukocyte counts. 3.